PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25445519-3	2014	Binary PCL/PD blend nonwovens showed a PD-dependent increase in swelling of up to 30% and of lysozyme burst release of up to 45% associated with changes of the fiber morphology.	polycaprolactone	7-10	lysozyme	Homo sapiens	93-101	
25445519-5	2014	Using ternary PCL/PD/PLGA blends, matrix degradation could be significantly improved over PCL/PD blends, resulting in a biphasic release of lysozyme with constant release over 9 weeks, followed by constant release with a reduced rate over additional 4 weeks.	polycaprolactone	14-17	lysozyme	Homo sapiens	140-148	
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	307-311	lysozyme	Homo sapiens	68-76	
17665113-0	2008	Encapsulation and controlled release of lysozyme from electrospun poly(epsilon-caprolactone)/poly(ethylene glycol) non-woven membranes by formation of lysozyme-oleate complexes.	polycaprolactone	66-92	lysozyme	Homo sapiens	40-48	
17665113-1	2008	In this study, the concept of hydrophobic ion pairing was adopted for incorporating lysozyme into electrospun poly(epsilon-caprolactone) (PCL)/poly(ethylene glycol) (PEG) non-woven membranes.	polycaprolactone	110-136	lysozyme	Homo sapiens	84-92	
17665113-1	2008	In this study, the concept of hydrophobic ion pairing was adopted for incorporating lysozyme into electrospun poly(epsilon-caprolactone) (PCL)/poly(ethylene glycol) (PEG) non-woven membranes.	polycaprolactone	138-141	lysozyme	Homo sapiens	84-92	
17665113-2	2008	The solubility of lysozyme in organic solvent was enhanced through the formation of lysozyme-oleate complexes, which could be directly loaded into PCL/PEG membranes using electrospinning technique.	polycaprolactone	147-150	lysozyme	Homo sapiens	18-26	
17665113-2	2008	The solubility of lysozyme in organic solvent was enhanced through the formation of lysozyme-oleate complexes, which could be directly loaded into PCL/PEG membranes using electrospinning technique.	polycaprolactone	147-150	lysozyme	Homo sapiens	84-92	
17665113-4	2008	The addition of PEG into the PCL nanofibers not only improved the hydrophilicity of the membrane, but also played an important role on in vitro lysozyme release rate.	polycaprolactone	29-32	lysozyme	Homo sapiens	144-152	
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	241-266	lysozyme	Homo sapiens	68-76	
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	241-266	lysozyme	Homo sapiens	78-81	
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	268-272	lysozyme	Homo sapiens	68-76	
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	268-272	lysozyme	Homo sapiens	78-81	
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	307-311	lysozyme	Homo sapiens	78-81